Company intelligence / Profile preview

SensiGen

Ann Arbor, Michigan, United States

Ownership: Private
Development stage: Other

Overview

SensiGen's AttoSense HPV assay demonstrated the ability to quantify viral load of human papillomavirus in head and neck cancer patients. Research published in the Journal of Clinical Oncology by the University of Michigan Head and Neck Oncology Team showed that patients with higher HPV concentrations are more likely to respond to organ-sparing chemotherapy. The assay has sensitivity of 98%+ and specificity of 99%+ and can identify all 15 known cancer-causing HPV types in a single automated step.

Therapeutic areas: OncologyNephrologyGastroenterologyImmunology
Modalities: Molecular diagnostic assay
Industry: Molecular Diagnostics

Partnerships

University of Michigan Head and Neck Oncology Team (research collaboration)discussions with independent reference laboratories for broader commercialization

Beyond the preview

Go deeper on SensiGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SensiGen.

Explore the full profile